Comorbidities of COPD

European Respiratory Review

Volumn 22, Issue 130, 2013, Pages 454-475

  Cavaillès, Arnaud ^a   Brinchault Rabin, Graziella ^b   Dixmier, Adrien ^c   Goupil, François ^d   Gut Gobert, Christophe ^e   Marchand Adam, Sylvain ^f,g   Meurice, Jean Claude ^h   Morel, Hugues ⁱ   Person Tacnet, Christine ^j   Leroyer, Christophe ^c,e   Diot, Patrice ^c,g  

^a NANTES UNIVERSITY HOSPITAL   (France)

^b PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

^c Universite de Brest   (France)

^d CENTRE HOSPITALIER DU MANS   (France)

^e SERVICE DE RHUMATOLOGIE   (France)

^f UNIVERSITÉ DE TOURS   (France)

^g UNIVERSITY HOSPITAL OF TOURS   (France)

^h UNIVERSITÉ DE POITIERS   (France)

ⁱ HÔPITAL BROUSSAIS   (France)

^j ANGERS UNIVERSITY HOSPITAL   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDEPRESSANT AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CONTRAST MEDIUM; CORTICOSTEROID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ERYTHROPOIETIN; HYPNOTIC AGENT; INDACATEROL; METFORMIN; NICOTINE; OXYGEN; PARATHYROID HORMONE[1-34]; PLACEBO; SALMETEROL; SIMVASTATIN; STEROID; TIOTROPIUM BROMIDE; TRIAMCINOLONE; VARENICLINE; VITAMIN D;

ANEMIA; ANXIETY; BLOOD CLOTTING DISORDER; BONE DENSITY; CANCER SCREENING; CHRONIC BRONCHITIS; CHRONIC INFLAMMATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; COGNITIVE DEFECT; COMORBIDITY; COMPUTER ASSISTED TOMOGRAPHY; CORTICOSTEROID INDUCED OSTEOPOROSIS; DEPRESSION; DIABETES MELLITUS; DISEASE EXACERBATION; DRUG MEGADOSE; ENDOTHELIAL DYSFUNCTION; GENETIC PREDISPOSITION; HEALTH CARE COST; HEART FAILURE; HOSPITALIZATION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; LUNG CANCER; LUNG EMPHYSEMA; LUNG FIBROSIS; MALNUTRITION; METABOLIC SYNDROME X; MORTALITY; NONHUMAN; OBESITY; OSTEOPOROSIS; OXYGEN THERAPY; PROGNOSIS; PULMONARY HYPERTENSION; PULMONARY VASCULAR DISEASE; REVIEW; SIDE EFFECT; SLEEP DISORDER; SLEEP DISORDERED BREATHING; SMOKING; SMOKING CESSATION; TOBACCO DEPENDENCE; VENOUS THROMBOEMBOLISM; INFLAMMATION; PREDICTIVE VALUE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK ASSESSMENT; RISK FACTOR;

COMORBIDITY; HUMANS; INFLAMMATION; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK ASSESSMENT; RISK FACTORS; SMOKING;

EID: 84888796314     PISSN: 09059180     EISSN: 16000617     Source Type: Journal    
DOI: 10.1183/09059180.00008612     Document Type: Review

References (211)

1. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. www.goldcopd.org Date last updated: February 2013. Date last accessed: February 15, 2013.
2. Haute Autorité de Santé (France). Prescrire chez le sujet agé. www.has-sante.fr Date last updated: January 2006. Date last accessed: February 15, 2013.
3. van Durme YM, Verhamme KM, Stijnen T, et al. Prevalence, incidence, and lifetime risk for the development of COPD in the elderly: the Rotterdam study. Chest 2009; 135: 368-377.
4. Crisafulli E, Costi S, Luppi F, et al. Role of comorbidities in a cohort of patients with COPD undergoing pulmonary rehabilitation. Thorax 2008; 63: 487-492.
5. Celli BR, Thomas NE, Anderson JA, et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med 2008; 178: 332-338.
6. Tashkin DP, Celli B, Senn S, et al. UPLIFT Study Investigators. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008; 359: 1543-1554.
7. Peinado VI, Barbera JA, Ramirez J, et al. Endothelial dysfunction in pulmonary arteries of patients with mild COPD. Am J Physiol 1998; 274: L908-L913.
8. Barr RG, Mesia-Vela S, Austin JH, et al. Impaired flow-mediated dilation is associated with low pulmonary function and emphysema in ex-smokers: the Emphysema and Cancer Action Project (EMCAP) Study. Am J Respir Crit Care Med 2007; 176: 1200-1207.
9. Palange P, Testa U, Huertas A, et al. Circulating haemopoietic and endothelial progenitor cells are decreased in COPD. Eur Respir J 2006; 27: 529-541.
10. Vaidyula VR, Criner GJ, Grabianowski C, et al. Circulating tissue factor procoagulant activity is elevated in stable moderate to severe chronic obstructive pulmonary disease. Thromb Res 2009; 124: 259-261.
11. Kaczmarek P, Sladek K, Stepien E, et al. Fibrin clot properties are altered in patients with chronic obstructive pulmonary disease. Beneficial effects of simvastatin treatment. Thromb Haemost 2009; 102: 1176-1182.
12. Sabit R, Thomas P, Shale DJ, et al. The effects of hypoxia on markers of coagulation and systemic inflammation in patients with COPD. Chest 2010; 138: 47-51.
13. Tillie-Leblond I, Marquette CH, Perez T, et al. Pulmonary embolism in patients with unexplained exacerbation of chronic obstructive pulmonary disease: prevalence and risk factors. Ann Intern Med 2006; 144: 390-396.
14. Gunen H, Gulbas G, In E, et al. Venous thromboemboli and exacerbations of COPD. Eur Respir J 2010; 35: 1243-1248.
15. Chaouat A, Naeije R, Weitzenblum E. Pulmonary hypertension in COPD. Eur Respir J 2008; 32: 1371-1385.
16. Chaouat A, Bugnet AS, Kadaoui N, et al. Severe pulmonary hypertension and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005; 172: 189-194.
17. Jyothula S, Safdar Z. Update on pulmonary hypertension complicating chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2009; 4: 351-363.
18. Oswald-Mammosser M, Weitzenblum E, Quoix E, et al. Prognostic factors in COPD patients receiving long-term oxygen therapy. Importance of pulmonary artery pressure. Chest 1995; 107: 1193-1198.
19. Kessler R, Oswald-Mammosser M. Does lung volume reduction surgery compromise the pulmonary circulation? Am J Respir Crit Care Med 1999; 160: 1429-1430.
20. Fisher MR, Forfia PR, Chamera E, et al. Accuracy of Doppler echocardiography in the hemodynamic assessment of pulmonary hypertension. Am J Respir Crit Care Med 2009; 179: 615-621.
21. Weitzenblum E, Sautegeau A, Ehrhart M, et al. Long-term oxygen therapy can reverse the progression of pulmonary hypertension in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 1985; 131: 493-498.
22. Sin DD, Man SF. Chronic obstructive pulmonary disease as a risk factor for cardiovascular morbidity and mortality. Proc Am Thorac Soc 2005; 2: 8-11.
23. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352: 1685-1695.
24. MacNee W, Maclay J, McAllister D. Cardiovascular injury and repair in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2008; 5: 824-833.
25. Eickhoff P, Valipour A, Kiss D, et al. Determinants of systemic vascular function in patients with stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008; 178: 1211-1218.
26. Brekke PH, Omland T, Smith P, et al. Underdiagnosis of myocardial infarction in COPD. Cardiac Infarction Injury Score (CIIS) in patients hospitalized for COPD exacerbation. Respir Med 2008; 102: 1243-1247.
27. Sin DD, Man SF. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation 2003; 107: 1514-1519.
28. Calverley PMA, Andeson JA, Celli B, et al. Cardiovascular events in patients with COPD: TORCH study results. Thorax 2010; 65: 719-725.
29. Singh S, Loke YK, Furberg CD. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systemic review. JAMA 2008; 301: 1227-1230.
30. Singh S, Loke YK, Enright PL, et al. Mortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis of randomised controlled trials. BMJ 2011; 342.
31. Le Jemtel TH, Padeletti M, Jelic S. Diagnostic and therapeutic challenges in patients with coexistent chronic obstructive disease and chronic heart failure. J Am Coll Cardiol 2007; 49: 171-180.
32. Freixa X, Portillo K, Paré C, et al. Echocardiographic abnormalities in patients with COPD at their first hospital admission. Eur Respir J 2013; 41: 784-791.
33. Rutten FH, Cramer MJ, Lammers JW, et al. Heart failure and chronic obstructive pulmonary disease: an ignored combination? Eur J Heart Fail 2006; 8: 707-711.
34. Sidney S, Sorel M, Quesenberry CP, et al. COPD and incident cardiovascular disease. Hospitalizations and mortality: Kaiser Permanente Medical Care Program. Chest 2005; 128: 2068-2075.
35. Garcia-Rodriguez LA, Wallander MA, Martin-Merino E, et al. Heart failure, myocardial infarction, lung cancer and death in COPD patients: a UK primary care study. Respir Med. 2010; 104: 1691-1699.
36. De Blois J, Simard S, Atar D, et al. COPD predicts mortality in HF: the Norwegian Heart Failure Registry. J Card Fail 2010; 16: 226-229.
37. Mascarenhas J, Lourenço P, Lopes R, et al. Chronic obstructive pulmonary disease in heart failure. Prevalence, therapeutic and prognostic implications. Am Heart J 2008; 155: 521-525.
38. Jabbour A, Macdonald PS, Keogh AM, et al. Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial. J Am Coll Cardiol 2010; 55: 1780-1787.
39. Ho KK, Pinsky JL, Kannel WB, et al. The epidemiology of heart failure: the Framingham Study. J Am Coll Cardiol 1993; 22: 6A-13A.
40. Flu WJ, van Gestel YR, van Kuijk JP, et al. Co-existence of COPD and left ventricular dysfunction in vascular surgery patients. Respir Med 2010; 104: 690-696.
41. Loganathan RS, Stover DE, Shi W, et al. Prevalence of COPD in women compared to men around the time of diagnosis of primary lung cancer. Chest 2006; 129: 1305-1312.
42. Young RP, Hopkins RJ, Christmas T, et al. COPD prevalence is increased in lung cancer, independent of age, sex and smoking history. Eur Respir J 2009; 34: 380-386.
43. Kiri VA, Soriano J, Visick G, et al. Recent trends in lung cancer and its association with COPD: an analysis using the UK GP Research Database. Prim Care Respir J 2010; 19: 57-61.
44. Mannino DM, Aguayo SM, Petty TL, et al. Low lung function and incident lung cancer in the United States: data From the First National Health and Nutrition Examination Survey follow-up. Arch Intern Med 2003; 163: 1475-1480.
45. de Torres JP, Marin JM, Casanova C, et al. Lung cancer in patients with COPD: incidence and predicting factors. Am J Respir Crit Care Med 2011; 184: 913-919.
46. Turner MC, Chen Y, Krewski D, et al. Chronic obstructive pulmonary disease is associated with lung cancer mortality in a prospective study of never smokers. Am J Respir Crit Care Med 2007; 176: 285-290.
47. Young RP, Hopkins RJ. How the genetics of lung cancer may overlap with COPD. Respirology 2011; 16: 1047-1055.
48. Cohen BH, Diamond EL, Graves CG, et al. A common familial component in lung cancer and chronic obstructive pulmonary disease. Lancet 1977; 2: 523-526.
49. Young RP, Hopkins RJ, Hay BA, et al. Lung cancer gene associated with COPD: triple whammy or possible confounding effect? Eur Respir J 2008; 32: 1158-1164.
50. Schwartz AG, Ruckdeschel JC. Familial lung cancer: genetic susceptibility and relationship to chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006; 173: 16-22.
51. Young RP, Whittington CF, Hopkins RJ, et al. Chromosome 4q31 locus in COPD is also associated with lung cancer. Eur Respir J 2010; 36: 1375-1382.
52. Punturieri A, Szabo E, Croxton TL, et al. Lung cancer and chronic obstructive pulmonary disease: needs and opportunities for integrated research. J Natl Cancer Inst 2009; 101: 554-559.
53. Yao H, Rahman I. Current concepts on the role of inflammation in COPD and lung cancer. Curr Opin Pharmacol 2009; 9: 375-383.
54. The National Lung Screening Trial Research Team, Aberle DR, Adams AM. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011; 365: 395-409.
55. Brunelli A, Charloux A, Bolliger CT, et al. ERS/ESTS clinical guidelines on fitness for radical therapy in lung cancer patients (surgery and chemo-radiotherapy). Eur Respir J 2009; 34: 17-41.
56. Wagena EJ, Van Der Meer RM, Ostelo RJ, et al. The efficacy of smoking cessation strategies in people with chronic obstructive pulmonary disease: results from a systematic review. Respir Med 2004; 98: 805-815.
57. Tashkin DP, Rennard S, Hays JT, et al. Effects of varenicline on smoking cessation in patients with mild to moderate COPD: a randomized controlled trial. Chest 2011; 139: 591-599.
58. Wu P, Wilson K, Dimoulas P, et al. Effectiveness of smoking cessation therapies: a systematic review and metaanalysis. BMC Public Health 2006; 6: 300.
59. Parimon T, Chien JW, Bryson CL, et al. Inhaled corticosteroids and risk of lung cancer among patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 175: 712-719.
60. Kiri VA, Fabbri LM, Davis KJ, et al. Inhaled corticosteroids and risk of lung cancer among COPD patients who quit smoking. Respir Med 2009; 103: 85-90.
61. Yao R, Wang Y, Lemon WJ, et al. Budesonide exerts its chemopreventive efficacy during mouse lung tumorigenesis by modulating gene expressions. Oncogene 2004; 23: 7746-7752.
62. Sprague BL, Trentham-Dietz A, Klein BE, et al. Physical activity, white blood cell count, and lung cancer risk in a prospective cohort study. Cancer Epidemiol Biomarkers Prev 2008; 17: 2714-2722.
63. Regvat J, Zmitek A, Vegnuti M, et al. Anxiety and depression during hospital treatment of exacerbation of chronic obstructive pulmonary disease. J Int Med Res 2011; 39: 1028-1038.
64. Spitzer C, Glaser S, Grabe HJ, et al. Mental health problems, obstructive lung disease and lung function: findings from the general population. J Psychosom Res 2011; 71: 174-179.
65. Schneider C, Jick SS, Bothner U. COPD and the risk of depression. Chest 2010; 137: 341-347.
66. Kunik ME. Surprisingly high prevalence of anxiety and depression in chronic breathing disorders. Chest 2005; 127: 1205-1211.
67. Van Manen JG. Risk of depression in patients with chronic obstructive pulmonary disease and its determinants. Thorax 2002; 57: 412-416.
68. Abrams TE, Vaughan-Sarrazin M, Vander Weg MW. Acute exacerbations of chronic obstructive pulmonary disease and the effect of existing psychiatric comorbidity on subsequent mortality. Psychosomatics 2011; 52: 441-449.
69. Ng TP, Niti M, Wan-Cheng T, et al. Depressive symptoms and chronic obstructive pulmonary disease. Arch Intern Med 2007; 167: 60-67.
70. Spitzer RL, Kroenke K, Williams JB. Validation and utility of a self-report version of the PRIME-MD: the PHQ primary care study; Primary Care Evaluation of Mental Disorders. Patient Health Questionnaire. JAMA 1999; 282: 1737-1744.
71. Koenig HG, Cohen HJ, Blazer DG, et al. Profile of depressive symptoms in younger and older medical inpatients with major depression. J Am Geriatr Soc 1993; 41: 1169-1176.
72. Yohannes AM, Roomi J, Baldwin RC, et al. Depression in elderly outpatients with disabling chronic obstructive pulmonary disease. Age Ageing 1998; 27: 155-160.
73. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Pyschiatr Scand 1983; 67: 361-370.
74. Antonelli Incalzi R. Drawing impairment predicts mortality in severe COPD. Chest 2006; 128: 62-69.
75. Haute Autorité de Santé (France). Fiche de synthèse: comment prévenir les fractures dues à l'ostéoporose? www.plan-retraite.fr/prevenir_fractures_osteoporose.pdf Date last updated: May 2007. Date last accessed: February 15, 2013.
76. Graat-Verboom L, Wouters EFM, Smeenk FW, et al. Current status of research on osteoporosisin COPD: a systematic review. Eur Respir J 2009; 34: 209-218.
77. Scanlon PD, Connett JE, Wise RA, et al. Loss of bone density with inhaled triamcinolone in Lung Health Study II. Am J Respir Crit Care Med 2004; 170: 1302-1309.
78. Ferguson GT, Calverley PMA, Anderson JA, et al. Prevalence and progression of osteoporosis in patients with COPD. Results from the towards a revolution in COPD Health Study. Chest 2009; 136: 1456-1465.
79. Mineo TC, Ambrogi V, Mineo D, et al. Bone mineral density improvement after lung volume reduction surgery for severe emphysema. Chest 2005; 127: 1960-1966.
80. Maggi S, Siviero P, Gonnelli S, et al. EOLO Study Group. Osteoporosis risk in patients with chronic obstructive pulmonary disease: the EOLO study. J Clin Densitom 2009; 12: 345-352.
81. Ionescu AA, Schoon E. Osteoporosis in chronic obstructive pulmonary disease. Eur Respir J 2003; 22: Suppl. 46, 64s-75s
82. Janssens W, Bouillon R, Claes B, et al. Vitamin D deficiency is highly prevalent in COPD and correlates with variants in the vitamin D-binding gene. Thorax 2010; 65: 215-220.
83. Barnes PJ. Chronic obstructive pulmonary disease: effects beyond the lungs. PLoS Med 2010; 7: e1000220.
84. Avenell A, Gillespie WJ, Gillespie LD, et al. Vitamin D and vitamin D analogues for preventing fractures associated with involutional and post-menopausal osteoporosis. Cochrane Database Syst Rev 2009; 2: CD000227.
85. Smith BJ, Laslett LL, Pile KD, et al. Randomized controlled trial of alendronate in airways disease and low bone mineral density. Chron Respir Dis 2004; 1: 131-137.
86. Grossman JM, Gordon R, Ranganath VK, et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken) 2010; 62: 1515-1526.
87. Schols AM, Soeters PB, Dingemans AM, et al. Prevalence and characteristics of nutritional depletion in patients with stable COPD eligible for pulmonary rehabilitation. Am Rev Respir Dis 1993; 147: 1151-1156.
88. Celli B, Cote C, Marin J, et al. The body mass index, airflow obstruction, dyspnea and exercice capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004; 350: 1005-1012.
89. Wagner PD. Possible mechanisms underlying the development of cachexia in COPD. Eur Respir J 2008; 31: 492-501.
90. Cano N, Pichard C, Roth H, et al. C reactive protein and body mass index predict outcome in end stage respiratory failure. Chest 2004; 126: 540-546.
91. Vestbo J, Prescott E, Almdal T, et al. Body mass, fat-free body mass, and prognosis in patients with chronic obstructive pulmonary disease from a random population sample: findings from the Copenhagen Cty Heart Study. Am J Respir Crit Care Med 2006; 173: 79-83.
92. Schols AM, Broekhuizen R, Weling-Scheepers CA, et al. Body composition and mortality in chronic obstructive pulmonary disease. Am J Clin Nutr 2005; 82: 53-59.
93. Landbo C, Prescott E, Lange P, et al. Prognostic value of nutritional status in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 160: 1856-1861.
94. Chailleux E, Laaban JP, Veale D. Prognostic value of nutritional depletion in patients with COPD treated by long term oxygen therapy: data from the ANTADIR observatory. Chest 2003; 123: 1460-1466.
95. Soler-Cataluna JJ, Sanchez-Sanchez L, Martinez Garcia M, et al. Mid arm muscle area is a better predictor of mortality than body mass index in COPD. Chest 2005; 128: 2108-2115.
96. Wilson DO, Rogers RM, Sanders MH, et al. Nutritional intervention in malnourished patients with emphysema. Am Rev Respir Dis 1986; 134: 672-677.
97. Eftymiou J, Fleming J, Gomes C, et al. The effect of supplementary oral nutrition in poorly nourished patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 1988; 137: 1075-1082.
98. Fereira IM, Brooks D, Lacasse Y, et al. Nutritional support for individuals with COPD: a meta-analysis. Chest 2000; 117: 672-678.
99. Broekhuizen R, Wouters EF, Creutzberg EC, et al. Polyunsaturated fatty acids improve exercise capacity in chronic obstructive pulmonary disease. Thorax 2005; 60: 376-382.
100. Creutzberg EC, Wouters EF, Mostert R, et al. A role for anabolic steroids in the rehabilitation of patients with COPD? A double blind, placebo controlled, randomised trial. Chest 2003; 124: 1733-1742.
101. Weisberg J, Wanger J, Olson J, et al. Megestrol acetate stimulates weight gain and ventilation in underweight COPD patients. Chest 2002; 121: 1070-1078.
102. Schols AM. Nutritional rehabilitation: from pulmonary cachexia to sarcoPD. Eur Respir J 2009; 33: 949-950.
103. Pison CM, Cano NJ, Chérion C, et al. Multimodal nutritional rehabilitation improves clinical outcomes of malnourished patients with chronic respiratory failure: a randomised controlled trial. Thorax 2011; 66: 953-960.
104. Ora J, Laveneziana P, Ofir D, et al. Combined effects of obesity and chronic obstructive pulmonary disease on dyspnea and exercise tolerance. Am J Respir Crit Care Med 2009; 180: 964-971.
105. Jee S, Sull JW, Park J, et al. Body mass index and mortality in Korean men and women. N Engl J Med 2006; 355: 779-787.
106. Jordan JG, Mann JR. Obesity and mortality in persons with obstructive lung disease using data from the NHANES III. South Med J 2010; 103: 232-230.
107. World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications. Report of a WHO consultation. Geneva, WHO, 1999.
108. International Diabetes Federation. The IDF consensus.Worldwide definition of the metabolic syndrome. www.idf.org
109. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome: a new world wide definition: a consensus statement from the IDF. Diabetic Medicine 2006; 23: 469-480.
110. Mannino DM, Thorn D, Swensen A, et al. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir J 2008; 32: 962-969.
111. Feary JR, Rodrigues LC, Smith CJ, et al. Prevalence of major comorbidities in subjects with COPD and incidence of myocardial infarction and stroke: a comprehensive analysis using data from primary care. Thorax 2010; 65: 956-962.
112. Cazzola M, Bettoncelli G, Sessa E, et al. Prevalence of comorbidities in patients with COPD. Respiration 2010; 80: 112-119.
113. Ghanassia E, Jaussent A, Picot MC, et al. [Prévalence de l'insulinorésistance et du syndrome métabolique chez le sujet BPCO]. Rev Mal Respir 2006; 23, 4: 393.
114. Watz H, Waschki B, Kirsten A, et al. The metabolic syndrome in patients with chronic bronchitis and COPD. Chest 2009; 136, 4: 1039-1046.
115. Song Y, Klevak A, Manson JE, et al. Asthma, chronic obstructive pulmonary disease, and type 2 diabetes in the Women's Health Study. Diabetes Res Clin Pract 2010; 90: 365-371.
116. Ehrlich SF, Quesenberry CP Jr, Van Den Eeden SK, et al. Patients diagnosed with diabetes are at increased risk for asthma, COPD, pulmonary fibrosis and pneumonia but not lung cancer. Diabetes care 2010; 33, 1: 55-60.
117. Seshasai SR, Kaptoge S, Thompson A, et al. Diabetes mellitus, fasting glucose and risk of cause specific death. N Engl J Med 2011; 364: 829-841.
118. Baker EH, Janaway CH, Philips BJ, et al. Hyperglycemia is associated with poor outcomes in patients admitted to hospital with acute exacerbations of COPD. Thorax 2006; 61: 284-289.
119. Parappil A, Depczynski B, Collett P, et al. Effect of comorbid diabetes on length of stay and risk of death in patients with acute exacerbations of COPD. Respirology 2010; 15: 918-922.
120. Manson JE, Ajani UA, Liu S, et al. A prospective study of cigarette smoking and the incidence of diabetes mellitus among US male physicians. Am J Med 2000; 109: 538-542.
121. Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest 2006; 116: 1793-1801.
122. Pradhan A. Obesity, metabolic syndrome, and type 2 diabetes: inflammatory basis of glucose metabolic disorders. Nutr Rev 2007; 65: S152-S156.
123. Fabbri LM, Luppi F, Beghé B, et al. Complex chronic comorbidities of COPD. Eur Respir J 2008; 31: 204-212.
124. Tkacova R. Systemic inflammation in chronic obstructive pulmonary disease: may adipose tissue play a role? Review of the literature and future perspectives. Mediators Inflamm 2010; 2010: 585-989.
125. Walter RE, Beiser A, Givelber RJ, et al. Association between glycemic state and lung function: the Framingham Heart Study. Am J Respir Crit Care Med 2003; 167: 911-916.
126. Yeh HC, Punjabi NM, Wang NY, et al. Cross-sectional and prospective study of lung function in adults with type 2 diabetes: the Atherosclerosis Risk in Communities (ARIC) study. Diabetes Care 2008; 31: 741-746.
127. van den Borst B, Gosker HR, Zeegers MP, et al. Pulmonary function in diabetes: a metaanalysis. Chest 2010; 138, 2: 393-406.
128. Leone N, Courbon D, Thomas F, et al. Lung function impairment and metabolic syndrome: the critical role of abdominal obesity. Am J Respir Crit Care Med 2009; 179: 509-516.
129. Funakoshi Y, Omori H, Mihara S, et al. Association between airflow obstruction and the metabolic syndrome or its components in Japanese men. Intern Med 2010; 49: 2093-2099.
130. Lam KB, Jordan RE, Jiang CQ, et al. Airflow obstruction and metabolic syndrome: the Guangzhou Biobank Cohort Study. Eur Respir J 2010; 35: 317-323.
131. Cuvelier A. [Pathologies extra-thoraciques au cours de la BPCO]. Rev Mal Respir 2006; 23: 25-31.
132. Burt MG, Roberts GW, Aguilar-Loza NR, et al. Continuous monitoring of circadian glycemic patterns in patients receiving prednisolone for COPD. J Clin Endocrinol Metab 2011; 96: 1789-1796.
133. Suissa S, Kezouh A, Ernst P. Inhaled corticosteroids and the risks of diabetes onset and progression. Am J Med 2010; 123: 1001-1006.
134. Lemyze M, Baudry JF, Collet F, et al. Life threatening lactic acidosis. BMJ 2010; 340: c857.
135. Bruijstens LA, van Luin M, Buscher-Jungerhans PMM, et al. Reality of severe metformin induced lactic acidosis in the absence of chronic renal impairment. J Med 2008; 66, 5: 185-190.
136. Jones GC, Macklin JP, Alexander WD. Contraindications to the use of metformin: evidence suggests that it is time to amend the list. BMJ 2003; 326: 4-5.
137. Sulkin TV, Bosman D, Krentz AJ. Contraindications to metformin therapy in patients with NIDDM. Diabetes Care 1997; 20: 925-928.
138. Holstein A, Nahrwold D, Hinze S, et al. Contraindications to metformin therapy are largely disregarded. Diabet Med 1999; V16: 692-696.
139. Rachmani R, Slavachevski I, Levi Z, et al. Metformin in patients with type 2 diabetes mellitus: reconsideration of traditional contraindications. Eur J Int Med 2002; 13: 428-433.
140. Van Berlo-Van de Laar IRF, Vermeij CG, Doorenbos CJ. Metformin associated lactic acidosis: incidence and clinical correlation with metformin serum concentration measurements. J Clin Pharm Ther 2011; 36: 376-382.
141. Stades AME, Heikens JT, Erkelens DW, et al. Metformin and lactic acidosis: cause or coincidence? A review of case reports. J Intern Med 2004; 255: 179-187.
142. Scale Y, Harvey JN. Diabetes, metformin and lactic acidosis. Clin Endocrinol (Oxf) 2011; 74: 191-196.
143. Young RP, Hopkins R, Eaton TE. Pharmacological actions of statins: potential utility in COPD. Eur Respir J 2009; 114: 222-232.
144. Barnes PJ, Celli BR. Systemic manifestations and comorbidities of COPD. Eur Respir J 2009; 33: 1165-1185.
145. Mancini GB, Etminan M, Zhang B, et al. Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. J Am Coll Cardiol 2006; 47: 2554-2560.
146. Rutten FH, Zuithoff NP, Hak E, et al. Beta-blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease. Arch Intern Med 2010; 170: 880-887.
147. Cormick W, Olson LG, Hensley MJ, et al. Nocturnal hypoxaemia and quality of sleep in patients with chronic obstructive lung disease. Thorax 1986; 41: 846-854.
148. Klink ME, Dodge R, Quan SF. The relation of sleep complaints to respiratory symptoms in a general population. Chest 1994; 105: 151-154.
149. Dodge R, Cline MG, Quan SF. The natural history of insomnia and its relationship to respiratory symptoms. Arch Intern Med 1995; 155: 1797-1800.
150. Sanders MH, Newman AB, Haggerty CL, et al. Sleep and sleep-disordered breathing in adults with predominantly mild obstructive airway disease. Am J Respir Crit Care Med 2003; 167: 7-14.
151. Krachman S, Minai OA, Scharf SM. Sleep abnormalities and treatment in emphysema. Proc Am Thorac Soc 2008; 5: 536-542.
152. Krachman SL, Chatila W, Martin UJ, et al. Physiologic correlates of sleep quality in severe emphysema. COPD 2011; 8: 182-188.
153. Valipour A, Lavie P, Lothaller H, et al. Sleep profile and symptoms of sleep disorders in patients with stable mild to moderate chronic obstructive pulmonary disease. Sleep Med 2011; 12: 367-372.
154. Budhiraja R, Roth T, Hudgel DW, et al. Prevalence and polysomnographic correlates of insomnia comorbid with medical disorders. Sleep 2011; 34: 859-867.
155. Kwon JS, Wolfe LF, Lu BS, et al. Hyperinflation is associated with lower sleep efficiency in COPD with co-existent obstructive sleep apnea. COPD 2009; 6: 441-445.
156. Krachman SL, Chatila W, Martin UJ, et al. National Emphysema Treatment Trial Research Group. Effects of lung volume reduction surgery on sleep quality and nocturnal gas exchange in patients with severe emphysema. Chest 2005; 128: 3221-3228.
157. Lewis CA, Fergusson W, Eaton T, et al. Isolated nocturnal desaturation in COPD: prevalence and impact on quality of life and sleep. Thorax 2009; 64: 133-138.
158. Lo Coco D, Mattaliano A, Lo Coco A, et al. Increased frequency of restless legs syndrome in chronic obstructive pulmonary disease patients. Sleep Med 2009; 10: 572-576.
159. Scharf SM, Maimon N, Simon-Tuval T, et al. Sleep quality predicts quality of life in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2010; 6: 1-12.
160. Chaouat A, Weitzenblum E, Kessler R, et al. A randomized trial of nocturnal oxygen therapy in chronic obstructive pulmonary disease patients. Eur Respir J 1999; 14: 1002-1008.
161. Fletcher EC, Luckett RA, Goodnight-White S, et al. A double-blind trial of nocturnal supplemental oxygen for sleep desaturation in patients with chronic obstructive pulmonary disease and a daytime Pa,O2 above 60 mmHg. Am Rev Respir Dis 1992; 145: 1070-1076.
162. McNicholas WT, Calverley PM, Lee A, et al. Tiotropium Sleep Study in COPD Investigators. Long-acting inhaled anticholinergic therapy improves sleeping oxygen saturation in COPD. Eur Respir J 2004; 23: 825-831.
163. Ryan S, Doherty LS, Rock C, et al. Effects of salmeterol on sleeping oxygen saturation in chronic obstructive pulmonary disease. Respiration 2010; 79: 475-481.
164. Donohue JF, Fogarty C, Lötvall J, et al. INHANCE Study Investigators. Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am J Respir Crit Care Med 2010; 182: 155-162.
165. Kornmann O, Dahl R, Centanni S, et al. INLIGHT-2 study investigators. Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison. Eur Respir J 2011; 37: 273-279.
166. Wijkstra PJ, Lacasse Y, Guyatt GH, et al. A meta-analysis of nocturnal noninvasive positive pressure ventilation in patients with stable COPD. Chest 2003; 124: 337-343.
167. Clini E, Sturani C, Rossi A, et al. Rehabilitation and Chronic Care Study Group, Italian Association of Hospital Pulmonologists (AIPO). The Italian multicentre study on noninvasive ventilation in chronic obstructive pulmonary disease patients. Eur Respir J 2002; 20: 529-538.
168. McEvoy RD, Pierce RJ, Hillman D, et al. Australian trial of non-invasive Ventilation in Chronic Airflow Limitation (AVCAL) Study Group. Nocturnal non-invasive nasal ventilation in stable hypercapnic COPD: a randomised controlled trial. Thorax 2009; 64: 561-566.
169. Crisafulli E, Manni G, Kidonias M, et al. Subjective sleep quality during average volume assured pressure support (AVAPS) ventilation in patients with hypercapnic COPD: a physiological pilot study. Lung 2009; 187: 299-305.
170. Scharf SM, Maimon N, Simon-Tuval T, et al. Sleep quality predicts quality of life in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2010; 6: 1-12.
171. Nunes DM, Mota RM, de Pontes Neto OL, et al. Impaired sleep reduces quality of life in chronic obstructive pulmonary disease. Lung 2009; 187: 159-163.
172. Roth T. Hypnotic use for insomnia management in chronic obstructive pulmonary disease. Sleep Med 2009; 10: 19-25.
173. Stege G, Vos PJ, van den Elshout FJ, et al. Sleep, hypnotics and chronic obstructive pulmonary disease. Respir Med 2008; 102: 801-814.
174. Stege G, Heijdra YF, van den Elshout FJ, et al. Temazepam 10 mg does not affect breathing and gas exchange in patients with severe normocapnic COPD. Respir Med 2010; 104: 518-524.
175. Bednarek M, Plywaczewski R, Jonczak L, et al. There is no relationship between chronic obstructive pulmonary disease and obstructive sleep apnea syndrome: a population study. Respiration 2005; 72: 142-149.
176. Chaouat A, Weitzenblum E, Krieger J, et al. Association of chronic obstructive pulmonary disease and sleep apnea syndrome. Am J Respir Crit Care Med 1995; 151: 82-86.
177. Hawryłkiewicz I, Sliwiński P, Górecka D, et al. Pulmonary haemodynamics in patients with OSAS or an overlap syndrome. Monaldi Arch Chest Dis 2004; 61: 148-152.
178. Marin JM, Soriano JB, Carrizo SJ, et al. Outcomes in patients with chronic obstructive pulmonary disease and obstructive sleep apnea: the overlap syndrome. Am J Respir Crit Care Med 2010; 182: 325-331.
179. McNicholas WT. Chronic obstructive pulmonary disease and obstructive sleep apnea: overlaps in pathophysiology, systemic inflammation, and cardiovascular disease. Am J Respir Crit Care Med 2009; 180: 692-700.
180. Machado MC, Vollmer WM, Togeiro SM, et al. CPAP and survival in moderate-to-severe obstructive sleep apnoea syndrome and hypoxaemic COPD. Eur Respir J 2010; 35: 132-137.
181. Weitzenblum E, Chaouat A, Kessler R, et al. Overlap syndrome: obstructive sleep apnea in patients with chronic obstructive pulmonary disease. Proc Am Thorac Soc 2008; 5: 237-241.
182. World Health Organization. Iron deficiency anemia. assessment, prevention, and control. A guide for programme managers. Geneva, WHO, 2001.
183. Cote C, Zilberberg MD, Mody SH, et al. Haemoglobin level and its clinical impact in a cohort of patients with COPD. Eur Respir J 2007; 29: 923-929.
184. Chambellan A, Chailleux E, Similowski T. Prognostic value of the hematocrit in patients with severe COPD receiving long-term oxygen therapy. Chest 2005; 128: 1201-1208.
185. John M, Lange A, Hoernig S, et al. Prevalence of anemia in chronic obstructive pulmonary disease: comparison to other chronic diseases. Int J Cardiol 2006; 111: 365-370.
186. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med 2005; 352: 1011-1023.
187. John M, Hoernig S, Doehner W, et al. Anemia and inflammation in COPD. Chest 2005; 127: 825-829.
188. Markoulaki D, Kostikas K, Papatheodorou G, et al. Hemoglobin, erythropoietin and systemic inflammation in exacerbations of chronic obstructive pulmonary disease. Eur J Intern Med 2011; 22: 103-107.
189. Tanner H, Moschovitis G, Kuster GM, et al. The prevalence of anemia in chronic heart failure. Int J Cardiol 2002; 86: 115-121.
190. Cromie N, Lee C, Struthers AD. Anaemia in chronic heart failure: what is its frequency in the UK and its underlying causes? Heart 2002; 87: 377-378.
191. Ezekowitz JA, McAlister FA, Armstrong PW. Anemia is common in heart failure and is associated with poor outcomes: insights from a cohort of 12065 patients with new-onset heart failure. Circulation 2003; 107: 223-225.
192. Okonko DO, Anker SD. Anemia in chronic heart failure: pathogenetic mechanisms. J Card Fail 2004; 10: Suppl. 1, S5-S9.
193. Krishnan G, Grant BJ, Muti PC, et al. Association between anemia and quality of life in a population sample of individuals with chronic obstructive pulmonary disease. BMC Pulm Med 2006; 6: 23.
194. Schonhofer B, Wenzel M, Geibel M, et al. Blood transfusion and lung function in chronically anemic patients with severe chronic obstructive pulmonary disease. Crit Care Med 1998; 26: 1824-1828.
195. van der Meer P, Groenveld HF, Januzzi JL Jr, et al. Erythropoietin treatment in patients with chronic heart failure: a meta-analysis. Heart 2009; 95: 1309-1314.
196. Washko GR, Hunninghake GM, Fernandez IE, et al. COPDGene Investigators. Lung volumes and emphysema in smokers with interstitial lung abnormalities. N Engl J Med 2011; 364: 897-906.
197. Cottin V, Nunes H, Brillet PY, et al. Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity. Eur Respir J 2005; 26: 586-593.
198. Cottin V. Pragmatic prognostic approach of rheumatoid arthritis-associated interstitial lung disease. Eur Respir J 2010; 35: 1206-1208.
199. Kitaguchi Y, Fujimoto K, Hanaoka M, et al. Clinical characteristics of combined pulmonary fibrosis and emphysema. Respirology 2010; 15: 265-271.
200. Agusti A, Calverley PM, Celli B, et al. Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) investigators. Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res 2010; 11: 122.
201. Burgel PR, Roche N, Paillasseur JL, et al. INITIATIVES BPCO Scientific Committee. Clinical COPD phenotypes identified by cluster analysis: validation with mortality. Eur Respir J 2012; 40: 495-496.
202. Wedzicha JA, Seemungal TA, MacCallum PK, et al. Acute exacerbations of chronic obstructive pulmonary disease are accompanied by elevations of plasma fibrinogen and serum IL-6 levels. Thromb Haemost 2000; 84: 210-215.
203. Drost EM, Skwarski KM, Sauleda J, et al. Oxidative stress and airway inflammation in severe exacerbations of COPD. Thorax 2005; 60: 293-300.
204. Donaldson GC, Hurst JR, Smith CJ, et al. Increased risk of myocardial infarction and stroke following exacerbation of COPD. Chest 2010; 137: 1091-1097.
205. Kiyokawa H, Muro S, Oguma T, et al. Impact of COPD exacerbations on osteoporosis assessed by chest CT scan. COPD 2012; 9: 235-242.
206. Vermeeren MA, Schols AM, Wouters EF. Effects of an acute exacerbation on nutritional and metabolic profile of patients with COPD. Eur Respir J 1997; 10: 2264-2269.
207. Zvezdin B, Milutinov S, Kojicic M, et al. A post mortem analysis of major causes of early death in patients hospitalized with COPD exacerbation. Chest 2009; 136: 376-380.
208. Dahlén I, Janson C. Anxiety and depression are related to the outcome of emergency treatment in patients with obstructive pulmonary disease. Chest 2002; 122: 1633-1637.
209. Gudmundsson G, Gislason T, Janson C, et al. Risk factors for rehospitalisation in COPD: role of health status, anxiety and depression. Eur Respir J 2005; 26: 414-419.
210. Papaioannou AI, Bartziokas K, Tsikrika S, et al. The impact of depressive symptoms on recovery and outcome of hospitalised COPD exacerbations. Eur Respir J 2013; 41: 815-823.
211. Küpeli E, Ulubay G, Ulasli SS, et al. Metabolic syndrome is associated with increased risk of acute exacerbation of COPD: a preliminary study. Endocrine 2010; 38: 76-82.